Alvotech (ALVO)

Market Cap	2.98B
Revenue (ttm)	n/a
Net Income (ttm)	n/a
Shares Out	248.65M
EPS (ttm)	0.24
PE Ratio	50.00
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	98,077
Open	12.03
Previous Close	11.98
Day's Range	11.86 - 12.08
52-Week Range	5.20 - 14.04
Beta	-0.15
Analysts	Buy
Price Target	13.06 (+8.83%)
Earnings Date	n/a

About ALVO

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory cond...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 784
• Stock Exchange: NASDAQ
• Ticker Symbol: ALVO

Financial Performance

In 2021, Alvotech's revenue was $36.77 million, a decrease of -44.80% compared to the previous year's $66.62 million. Losses were -$101.50 million, -40.31% less than in 2020.

Analyst Forecast

According to 11 analysts, the average rating for ALVO stock is "Buy." The 12-month stock price forecast is $13.06, which is an increase of 8.83% from the latest price.

Price Target

$13.06

(8.83% upside)

Analyst Consensus: Buy